|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48.
2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Autier P, Boniol M, LaVecchia C, Vatten L,
Gavin A, Héry C and Heanue M: Disparities in breast cancer
mortality trends between 30 European countries: Retrospective trend
analysis of WHO mortality database. BMJ. 341(c3620)2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Orrantia-Borunda E, Anchondo-Nuñez P,
Acuña-Aguilar LE, Gómez-Valles FO and Ramírez-Valdespino CA:
Subtypes of breast cancer. In: Breast Cancer. Mayrovitz HN (ed).
Exon Publications, Brisbane, 2022. Available from: http://www.ncbi.nlm.nih.gov/books/NBK583808/.
|
|
4
|
Plasilova ML, Hayse B, Killelea BK,
Horowitz NR, Chagpar AB and Lannin DR: Features of triple-negative
breast cancer. Medicine (Baltimore). 95(e4614)2016.
|
|
5
|
Ellsworth DL, Turner CE and Ellsworth RE:
A Review of the hereditary component of triple negative breast
cancer: High- and Moderate-penetrance breast cancer genes,
Low-Penetrance loci, and the role of nontraditional genetic
elements. J Oncol. 2019(e4382606)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Millikan RC, Newman B, Tse CK, Moorman PG,
Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT,
et al: Epidemiology of basal-like breast cancer. Breast Cancer Res
Treat. 109:123–139. 2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jiagge E, Jibril AS, Chitale D,
Bensenhaver JM, Awuah B, Hoenerhoff M, Adjei E, Bekele M, Abebe E,
Nathanson SD, et al: Comparative analysis of breast cancer
phenotypes in African American, white American, and west versus
east African patients: Correlation between African ancestry and
triple-negative breast cancer. Ann Surg Oncol. 23:3843–3849.
2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tung N, Lin NU, Kidd J, Allen BA, Singh N,
Wenstrup RJ, Hartman AR, Winer EP and Garber JE: Frequency of
germline mutations in 25 cancer susceptibility genes in a
sequential series of patients with breast cancer. J Clin Oncol.
34:1460–1468. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
TruSight Cancer | Sequence cancer
predisposition-related genes. https://www.illumina.com/products/by-type/clinical-research-products/trusight-cancer.html.
Accessed October 22, 2023.
|
|
10
|
Richards S, Aziz N, Bale S, Bick D, Das S,
Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al:
Standards and guidelines for the interpretation of sequence
variants: A joint consensus recommendation of the American college
of medical genetics and genomics and the association for molecular
pathology. Genet Med. 17:405–424. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Denkert C, Liedtke C, Tutt A and von
Minckwitz G: Molecular alterations in triple-negative breast
cancer-the road to new treatment strategies. Lancet. 389:2430–2442.
2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hahnen E, Hauke J, Engel C, Neidhardt G,
Rhiem K and Schmutzler RK: Germline mutations in triple-negative
breast cancer. Breast Care Basel Switz. 12:15–19. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Dodova RI, Mitkova AV, Dacheva DR, Hadjo
LB, Vlahova AI, -Hadjieva MST, Valev SS, Caulevska MM, Popova SD,
Popov IE, et al: Spectrum and frequencies of BRCA1/2 mutations in
Bulgarian high risk breast cancer patients. BMC Cancer.
15(523)2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kumar P and Aggarwal R: An overview of
triple-negative breast cancer. Arch Gynecol Obstet. 293:247–269.
2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Li X, Yang J, Peng L, Sahin AA, Huo L,
Ward KC, O'Regan R, Torres MA and Meisel JL: Triple-negative breast
cancer has worse overall survival and cause-specific survival than
non-triple-negative breast cancer. Breast Cancer Res Treat.
161:279–287. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hata C, Nakaoka H, Xiang Y, Wang D, Yang
A, Liu D, Liu F, Zou Q, Wei L, Zheng K, et al: Germline mutations
of multiple breast cancer-related genes are differentially
associated with triple-negative breast cancers and prognostic
factors. J Hum Genet. 65:577–587. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Shimelis H, LaDuca H, Hu C, Hart SN, Na J,
Thomas A, Akinhanmi M, Moore RM, Brauch H, Cox A, et al:
Triple-Negative breast cancer risk genes identified by multigene
hereditary cancer panel testing. J Natl Cancer Inst. 110:855–862.
2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hu C, Polley EC, Yadav S, Lilyquist J,
Shimelis H, Na J, Hart SN, Goldgar DE, Shah S, Pesaran T, et al:
The contribution of germline predisposition gene mutations to
clinical subtypes of invasive breast cancer from a clinical genetic
testing cohort. J Natl Cancer Inst. 112:1231–1241. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Vallega KA, Liu N, Myers JS, Yu K and Sang
QXA: Elevated resistin gene expression in african american estrogen
and progesterone receptor negative breast cancer. PLoS One.
11(e0157741)2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kwan ML, Kushi LH, Weltzien E, Maring B,
Kutner SE, Fulton RS, Lee MM, Ambrosone CB and Caan BJ:
Epidemiology of breast cancer subtypes in two prospective cohort
studies of breast cancer survivors. Breast Cancer Res.
11(R31)2009.PubMed/NCBI View
Article : Google Scholar
|
|
21
|
Sineshaw H, Gaudet M, Ward EM, Flanders
WD, Desantis C, Lin CC and Jemal A: Association of race/ethnicity,
socioeconomic status, and breast cancer subtypes in the National
Cancer Data Base (2010-2011). Breast Cancer Res Treat. 145:753–763.
2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Breast-screening. https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf.
Accessed July 19, 2023.
|
|
23
|
Derakhshan F and Reis-Filho JS:
Pathogenesis of triple-negative breast cancer. Annu Rev Pathol.
17:181–204. 2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Reis-Filho JS and Tutt ANJ: Triple
negative tumours: A critical review. Histopathology. 52:108–118.
2008.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Cuzick J: Epidemiology of breast
cancer-selected highlights. Breast. 12:405–411. 2003.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Baglia ML, Tang MTC, Malone KE, Porter P
and Li CI: Family history and risk of second primary breast cancer
after in situ breast carcinoma. Cancer Epidemiol Biomarkers Prev.
27:315–320. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lhotova K, Stolarova L, Zemankova P, Vocka
M, Janatova M, Borecka M, Cerna M, Jelinkova S, Kral J, Volkova Z,
et al: Multigene panel germline testing of 1333 Czech patients with
ovarian cancer. Cancers (Basel). 12(956)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Petrucelli N, Daly MB and Pal T: BRCA1-
and BRCA2-associated hereditary breast and ovarian cancer. In:
GeneReviews®. Adam MP, Mirzaa GM, Pagon RA, Wallace SE,
Bean LJ, Gripp KW, et al (eds). University of Washington,
Seattle, 1993. http://www.ncbi.nlm.nih.gov/books/NBK1247/.
|
|
29
|
Lucas AL, Frado LE, Hwang C, Kumar S,
Khanna LG, Levinson EJ, Chabot JA, Chung WK and Frucht H: BRCA1 and
BRCA2 germline mutations are frequently demonstrated in both
high-risk pancreatic cancer screening and pancreatic cancer
cohorts. Cancer. 120:1960–1967. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Pritchard CC, Mateo J, Walsh MF, De Sarkar
N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R,
et al: Inherited DNA-repair gene mutations in men with metastatic
prostate cancer. N Engl J Med. 375:443–453. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Founder BRCA1/2 mutations in the Europe:
Implications for hereditary breast-ovarian cancer prevention and
control-PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405339/.
Accessed July 19, 2023.
|
|
32
|
Bogdanova NV, Antonenkova NN, Rogov YI,
Karstens JH, Hillemanns P and Dörk T: High frequency and
allele-specific differences of BRCA1 founder mutations in breast
cancer and ovarian cancer patients from Belarus. Clin Genet.
78:364–372. 2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Plaschke J, Commer T, Jacobi C, Schackert
HK and Chang-Claude J: BRCA2 germline mutations among early onset
breast cancer patients unselected for family history of the
disease. J Med Genet. 37(E17)2000.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Borg A, Haile RW, Malone KE, Capanu M,
Diep A, Törngren T, Teraoka S, Begg CB, Thomas DC, Concannon P, et
al: Characterization of BRCA1 and BRCA2 deleterious mutations and
variants of unknown clinical significance in unilateral and
bilateral breast cancer: The WECARE study. Hum Mutat.
31:E1200–E1240. 2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Janavičius R, Rudaitis V, Mickys U,
Elsakov P and Griškevičius L: Comprehensive BRCA1 and BRCA2
mutational profile in Lithuania. Cancer Genet. 207:195–205.
2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ratajska M, Krygier M, Stukan M, Kuźniacka
A, Koczkowska M, Dudziak M, Śniadecki M, Dębniak J, Wydra D, Brozek
I, et al: Mutational analysis of BRCA1/2 in a group of 134
consecutive ovarian cancer patients. Novel and recurrent BRCA1/2
alterations detected by next generation sequencing. J Appl Genet.
56:193–198. 2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Breast_risk. [cited 2023 Jul 24].
https://www.nccn.org/professionals/physician_gls/pdf/breast_risk.pdf.
Accessed July 24, 2023.
|
|
38
|
Sessa C, Balmaña J, Bober SL, Cardoso MJ,
Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D,
Harbeck N, et al: Risk reduction and screening of cancer in
hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice
Guideline. Ann Oncol. 34:33–47. 2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Blackford AN, Schwab RA, Nieminuszczy J,
Deans AJ, West SC and Niedzwiedz W: The DNA translocase activity of
FANCM protects stalled replication forks. Hum Mol Genet.
21:2005–2016. 2012.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Whitby MC: The FANCM family of DNA
helicases/translocases. DNA Repair (Amst). 9:224–236.
2010.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Gari K, Décaillet C, Delannoy M, Wu L and
Constantinou A: Remodeling of DNA replication structures by the
branch point translocase FANCM. Proc Natl Acad Sci USA.
105:16107–16112. 2008.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ciccia A, Ling C, Coulthard R, Yan Z, Xue
Y, Meetei AR, Laghmani el H, Joenje H, McDonald N, de Winter JP, et
al: Identification of FAAP24, a Fanconi anemia core complex protein
that interacts with FANCM. Mol Cell. 25:331–343. 2007.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Kiiski JI, Pelttari LM, Khan S,
Freysteinsdottir ES, Reynisdottir I, Hart SN, Shimelis H, Vilske S,
Kallioniemi A, Schleutker J, et al: Exome sequencing identifies
FANCM as a susceptibility gene for triple-negative breast cancer.
Proc Natl Acad Sci USA. 111:15172–15177. 2014.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Burgstaller-Muehlbacher S, Marko M, Müller
C, Wendt J, Pehamberger H and Okamoto I: Novel CDKN2A mutations in
Austrian melanoma patients. Melanoma Res. 25:412–420.
2015.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Holland EA, Beaton SC, Becker TM, Grulet
OM, Peters BA, Rizos H, Kefford RF and Mann GJ: Analysis of the p16
gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene.
11:2289–2294. 1995.PubMed/NCBI
|
|
46
|
Jenkins NC, Jung J, Liu T, Wilde M, Holmen
SL and Grossman D: Familial melanoma-associated mutations in p16
uncouple its tumor-suppressor functions. J Invest Dermatol.
33:1043–1051. 2013.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Becker TM, Rizos H, Kefford RF and Mann
GJ: Functional impairment of melanoma-associated p16(INK4a) mutants
in melanoma cells despite retention of cyclin-dependent kinase 4
binding. Clin Cancer Res. 7:3282–3288. 2001.PubMed/NCBI
|
|
48
|
Dębniak T, Górski B, Huzarski T, Byrski T,
Cybulski C, Mackiewicz A, Gozdecka-Grodecka S, Gronwald J, Kowalska
E, Haus O, et al: A common variant of CDKN2A (p16) predisposes to
breast cancer. J Med Genet. 42:763–765. 2005.PubMed/NCBI View Article : Google Scholar
|
|
49
|
German J, Sanz MM, Ciocci S, Ye TZ and
Ellis NA: Syndrome-causing mutations of the BLM gene in persons in
the Bloom's syndrome registry. Hum Mutat. 28:743–753.
2007.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Ababou M: Bloom syndrome and the
underlying causes of genetic instability. Mol Genet Metab.
133:35–48. 2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Prokofyeva D, Bogdanova N, Dubrowinskaja
N, Bermisheva M, Takhirova Z, Antonenkova N, Turmanov N, Datsyuk I,
Gantsev S, Christiansen H, et al: Nonsense mutation p.Q548X in BLM,
the gene mutated in Bloom's syndrome, is associated with breast
cancer in Slavic populations. Breast Cancer Res Treat. 137:533–539.
2013.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Antczak A, Kluźniak W, Wokołorczyk D,
Kashyap A, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Dębniak
T, Masojć B, et al: A common nonsense mutation of the BLM gene and
prostate cancer risk and survival. Gene. 532:173–176.
2013.PubMed/NCBI View Article : Google Scholar
|
